University of Miami Study Finds Metformin May Benefit Prostate Cancer Patients
Researchers at the University of Miami Miller School of Medicine have discovered that metformin, a common anti-diabetic drug, may offer unexpected health benefits for prostate cancer patients. The study, published in EMBO Molecular Medicine, suggests that metformin can activate biological pathways similar to those triggered by exercise, potentially aiding patients who are unable to engage in physical activity due to their treatment. Metformin is widely prescribed for type 2 diabetes and is known to improve insulin handling and lower blood sugar levels. The study found that metformin increased levels of a molecule associated with energy balance and weight regulation in prostate cancer patients, which could be particularly beneficial for those unable to exercise. 
